The recent study on weight-loss drugs has raised concerns about their impact on muscle mass, revealing a more significant loss than expected. This finding highlights a critical aspect of weight-loss treatments that needs further exploration and clinical attention.
John Batsis, MD, an associate professor of medicine, led the study, which analyzed 36 randomized clinical trials involving incretin-based obesity medications. The study's key revelation was the extent of muscle mass loss, surpassing the 25% threshold that clinicians typically anticipate during weight reduction. This discovery is particularly striking given that no studies directly linked this muscle loss to decreased strength or physical function.
The research included diverse participants, with an average age ranging from 20 to 63.7 years. However, only a small percentage (9%) of studies involved individuals aged 60 or older, and none focused on adults aged 65 or older. This demographic gap is significant because muscle mass naturally diminishes with age, making any additional loss more critical in older adults.
Batsis and his team's findings indicate that 68% of individuals using these drugs experienced muscle mass loss exceeding the 25% benchmark, compared to 50% in those using lifestyle interventions or placebos. The absence of studies correlating muscle mass loss with strength or function loss leaves a clinical gap, emphasizing the need to assess strength and mobility alongside weight loss in patients receiving these therapies.
The study's implications are profound, especially for older adults, as muscle mass loss can significantly impact physical function. Jaime Almandoz, MD, a professor of medicine, emphasizes the importance of monitoring muscle function and strength in patients taking weight-loss drugs. Simple tests like grip strength, sit-to-stand tests, and timed up-and-go assessments can help clinicians track muscle health without relying on expensive equipment.
Despite the concerns, Almandoz acknowledges the benefits of these medications in reducing the risk of cardiovascular disease and improving cardiometabolic health and quality of life. However, he stresses the need for careful consideration and monitoring of muscle function to ensure the overall health and well-being of patients.
The study's findings prompt a reevaluation of clinical practices, suggesting that clinicians should refer patients to physical therapists, exercise specialists, and nutritionists while on weight-loss medications. This approach aims to minimize obesity-related complications while preserving muscle function and strength.
In conclusion, the study highlights a critical aspect of weight-loss drugs that requires further investigation and clinical attention. By addressing the potential risks and benefits, healthcare professionals can make informed decisions, ensuring that patients receive the best possible care while managing their weight effectively.
